These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39034222)

  • 21. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
    Haque W; Verma V; Butler EB; Teh BS
    J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of demographics and socioeconomic status on the receipt of immunotherapy for stage III melanoma.
    Coogan AC; Blinn PA; Ritz EM; Tan A; Lunt L; Akers R; O'Donoghue C
    Surg Oncol; 2024 Oct; 57():102156. PubMed ID: 39406048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.
    Dinan MA; Georgieva MV; Li Y; Zhang T; Harrison M; Shenolikar R; Scales CD
    J Geriatr Oncol; 2021 Mar; 12(2):298-304. PubMed ID: 32912737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
    Klapheke A; Yap SA; Pan K; Cress RD
    Urol Oncol; 2018 Jun; 36(6):308.e19-308.e25. PubMed ID: 29628318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
    Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Meza L; Malhotra J; Favorito C; Pal SK
    Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma.
    Patel HV; Kim S; Srivastava A; Shinder BM; Sterling J; Saraiya B; Mayer TM; Ghodoussipour S; Jang TL; Singer EA
    Clin Genitourin Cancer; 2022 Jun; 20(3):296-296.e9. PubMed ID: 35105510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
    Narita C; Urabe F; Fukuokaya W; Iwatani K; Imai Y; Yasue K; Mori K; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Yamada Y; Yuen SKK; Teoh JY; Shimomura T; Yamada H; Furuta A; Miki J; Kimura T;
    Clin Genitourin Cancer; 2024 Jun; 22(3):102082. PubMed ID: 38641443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
    Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethnic disparities in renal cell carcinoma: An analysis of Hispanic patients in a single-payer healthcare system.
    Suarez-Sarmiento A; Yao X; Hofmann JN; Syed JS; Zhao WK; Purdue MP; Chow WH; Corley D; Shuch B
    Int J Urol; 2017 Oct; 24(10):765-770. PubMed ID: 28913849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
    Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
    J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer.
    Ramkumar SP; Bhardwaj A; Patel A; Seetharaman K; Christman A; Amondikar N; Abouelella DK; Hussaini AS; Barnes JM; Adjei Boakye E; Watts TL; Osazuwa-Peters N
    JAMA Otolaryngol Head Neck Surg; 2023 Oct; 149(10):912-918. PubMed ID: 37651149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study.
    Lec PM; Lenis AT; Brisbane W; Sharma V; Golla V; Gollapudi K; Blumberg J; Drakaki A; Bergman J; Chamie K
    Urol Oncol; 2020 Nov; 38(11):854.e1-854.e9. PubMed ID: 32430252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Li R; Sexton W; Manley BJ; Gilbert SM
    Urol Oncol; 2022 Mar; 40(3):107.e11-107.e17. PubMed ID: 34426068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015.
    Xia L; Talwar R; Taylor BL; Shin MH; Berger IB; Sperling CD; Chelluri RR; Zambrano IA; Raman JD; Guzzo TJ
    Urol Oncol; 2019 Mar; 37(3):182.e17-182.e27. PubMed ID: 30630732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
    Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
    Target Oncol; 2021 Nov; 16(6):813-821. PubMed ID: 34741719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
    Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
    Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.
    Gild P; Wankowicz SA; Sood A; von Landenberg N; Friedlander DF; Alanee S; Chun FKH; Fisch M; Menon M; Trinh QD; Bellmunt J; Abdollah F
    Urol Oncol; 2018 Oct; 36(10):469.e1-469.e11. PubMed ID: 30139659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.